Orexo’s partner Gesynta Pharma prepares phase 2 study for OX-MPI aiming to develop an innovative treatment for endometriosis

Uppsala, Sweden – October 20, 2022 – Orexo’s partner Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), has announced the company has taken a strategic decision to develop a pharmaceutical for the treatment of endometriosis, a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age.

The decision is based on strong positive data from a recently conducted preclinical proof-of-concept study with OX-MPI (GS-248), in an advanced model of endometriosis, where disease-modifying properties of the drug candidate were firmly established. These data along with the good safety profile displayed in a former clinical trial, as well as the large treatment need, has formed the basis for start preparing for a phase 2 study in patients with endometriosis.

For more information, Gesynta Pharma´s press release is attached.